Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Adar1 Capital Management, Llc Acquires 331,979 Shares of Company Stock

Posted by Brenda Bartman on Oct 22nd, 2026

Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) major shareholder Adar1 Capital Management, Llc purchased 331,979 shares of the company’s stock in a transaction that occurred on Wednesday, October 21st. The shares were bought at an average cost of $1.66 per share, with a total value of $551,085.14. Following the transaction, the insider directly owned 7,447,000 shares of the company’s stock, valued at $12,362,020. The trade was a 4.67% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

On Tuesday, October 20th, Adar1 Capital Management, Llc purchased 254,342 shares of Tenax Therapeutics stock. The shares were bought at an average cost of $1.60 per share, for a total transaction of $406,947.20.
On Monday, October 19th, Adar1 Capital Management, Llc purchased 336,528 shares of Tenax Therapeutics stock. The shares were bought at an average cost of $1.51 per share, for a total transaction of $508,157.28.
On Thursday, September 3rd, Adar1 Capital Management, Llc purchased 900,000 shares of Tenax Therapeutics stock. The stock was bought at an average price of $1.78 per share, for a total transaction of $1,602,000.00.
On Wednesday, September 2nd, Adar1 Capital Management, Llc acquired 187,704 shares of Tenax Therapeutics stock. The shares were bought at an average cost of $1.80 per share, with a total value of $337,867.20.
On Tuesday, September 1st, Adar1 Capital Management, Llc acquired 179,058 shares of Tenax Therapeutics stock. The shares were bought at an average cost of $1.80 per share, with a total value of $322,304.40.
On Monday, August 31st, Adar1 Capital Management, Llc acquired 403,571 shares of Tenax Therapeutics stock. The shares were purchased at an average price of $1.79 per share, with a total value of $722,392.09.
On Monday, August 24th, Adar1 Capital Management, Llc acquired 107,374 shares of Tenax Therapeutics stock. The shares were purchased at an average price of $1.75 per share, with a total value of $187,904.50.
On Friday, August 21st, Adar1 Capital Management, Llc bought 716,369 shares of Tenax Therapeutics stock. The stock was purchased at an average cost of $1.77 per share, for a total transaction of $1,267,973.13.
On Thursday, August 20th, Adar1 Capital Management, Llc bought 202,124 shares of Tenax Therapeutics stock. The stock was purchased at an average cost of $1.78 per share, for a total transaction of $359,780.72.

Tenax Therapeutics Stock Performance

Shares of Tenax Therapeutics stock opened at $1.63 on Thursday. Tenax Therapeutics, Inc. has a twelve month low of $1.31 and a twelve month high of $19.40. The stock has a market capitalization of $61.00 million, a P/E ratio of -1.10 and a beta of 0.92. The business’s fifty day moving average price is $1.85 and its 200 day moving average price is $9.15.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.03. As a group, sell-side analysts predict that Tenax Therapeutics, Inc. will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Tenax Therapeutics

Large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its holdings in shares of Tenax Therapeutics by 391.2% during the 1st quarter. Bank of America Corp DE now owns 18,569 shares of the specialty pharmaceutical company’s stock valued at $297,000 after buying an additional 14,789 shares during the period. Renaissance Technologies LLC boosted its holdings in Tenax Therapeutics by 21.5% in the 1st quarter. Renaissance Technologies LLC now owns 152,600 shares of the specialty pharmaceutical company’s stock worth $2,440,000 after acquiring an additional 27,021 shares during the period. The Manufacturers Life Insurance Company purchased a new position in Tenax Therapeutics in the 1st quarter worth approximately $501,000. Squarepoint Ops LLC purchased a new position in Tenax Therapeutics in the 2nd quarter worth approximately $485,000. Finally, State of Alaska Department of Revenue acquired a new stake in Tenax Therapeutics in the third quarter valued at approximately $94,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Guggenheim cut Tenax Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 31st. Weiss Ratings lowered shares of Tenax Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, September 14th. Canaccord Genuity Group set a $4.00 price target on shares of Tenax Therapeutics and gave the company a “buy” rating in a report on Tuesday, August 11th. Chardan Capital cut shares of Tenax Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 price target on the stock. in a research report on Tuesday, August 11th. Finally, Wall Street Zen cut shares of Tenax Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $14.00.

View Our Latest Report on TENX

About Tenax Therapeutics

(Get Free Report)

Tenax Therapeutics, Inc is a specialty pharmaceutical company focused on developing treatments for cardiovascular and pulmonary diseases with significant unmet medical needs. The company’s research and development activities are centered on therapies intended to improve outcomes for patients with conditions affecting the heart and lungs.

Tenax’s primary product candidate is an oral formulation of levosimendan, a drug designed to enhance cardiac contractility and produce vasodilatory effects.